Press Enter to search · Esc to close
A new wave of peer-reviewed evidence shows GLP-1 drugs reaching further into metabolic medicine—while exposing risks that busy men should know before they fill the prescription.
Two new studies sharpen the picture of mTOR as an aging lever — pointing toward more precise ways to dial it down than blunt suppression.
A new clinical clock called LinAge2 is trained to predict survival, not just guess your age — a quiet but meaningful shift for anyone paying for an epigenetic age test.
A new European synthesis maps the levers — personal, clinical, and environmental — that may compress the years we spend sick at the end of a longer life.
Two 2025 studies converge on measurable biological signatures that set centenarians—and long-lived mammals—apart. The evidence is intriguing, the mechanisms partial, the hype unwarranted.
The same cellular switch that supplement brands sell as 'longevity insurance' may quietly favor lung tumors. A new GeroScience analysis forces a harder look at sulforaphane, curcumin, and the broader NRF2 boom.
A new wave of 2025 research suggests semaglutide and its siblings do far more than shrink waistlines. The evidence is moderate, the implications are not.
A new wave of reviews argues that aging biology — not individual diseases — is medicine's highest-leverage target. Heart failure may be the proving ground.
Beyond fat loss and blood sugar, GLP-1 receptor agonists are stacking evidence in failing hearts, rare obesity syndromes, Alzheimer's, and even bone. Here's what's real — and what's still hype.
A phase 3 Parkinson's trial, a kidney meta-analysis, an ocular cohort and new mechanistic work suggest the GLP-1 class is becoming a multi-system intervention — with important caveats.